SGHT trades 17.6% above Wall Street's consensus target of $7.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes SGHT achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 9 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, Sight Sciences, Inc. (SGHT) has a Wall Street consensus price target of $7.00, based on estimates from 9 covering analysts. With the stock currently trading at $8.50, this represents a potential downside of -17.6%. The company has a market capitalization of $462M.
Analyst price targets range from a low of $7.00 to a high of $7.00, representing a 0% spread in expectations. The median target of $7.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 4 analysts rating the stock as a Buy or Strong Buy,4 rating it Hold, and 1 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, SGHT trades at a trailing P/E of -11.5x. Analysts expect EPS to grow -17.8% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 GKOSGlaukos Corporation | $9.1B | $153.49 | $190.75 | +24.3% | Buy | — | 25 |
 ATRCAtriCure, Inc. | $3.0B | $59.95 | $57.29 | -4.4% | Buy | 560.9x | 19 |
 NVCRNovocure Ltd | $1.9B | $16.25 | $26.00 | +60.0% | Buy | — | 15 |
 HOLXHologic, Inc. | $17.0B | $76.01 | $78.69 | +3.5% | Hold | 17.2x | 42 |
 MASIMasimo Corporation | $9.4B | $179.95 | $176.00 | -2.2% | Buy | 32.7x | 23 |
 TNDMTandem Diabetes Care, Inc. | $1.1B | $16.38 | $30.17 | +84.2% | Buy | — | 39 |
 ABTAbbott Laboratories | $180.3B | $103.53 | $121.50 | +17.4% | Buy | 18.8x | 41 |
 MDTMedtronic plc | $114.7B | $89.30 | $98.00 | +9.7% | Buy | 14.9x | 51 |
 SYKStryker Corporation | $104.8B | $273.40 | $372.39 | +36.2% | Buy | 18.2x | 52 |
 BSXBoston Scientific Corporation | $66.3B | $44.62 | $66.30 | +48.6% | Buy | 13.6x | 44 |
Quick answers to the most common questions about buying SGHT stock.
SGHT's consensus price target is $7, -17.6% below the current price of $8.5. The 9 analysts tracking SGHT see downside risk at present valuations.
SGHT has a consensus rating of "Buy" based on 9 Wall Street analysts. The rating breakdown is mixed, with 4 Hold ratings making up the largest segment. The consensus 12-month price target of $7 implies -17.6% downside from current levels.
SGHT's current price is $8.5 with a consensus target of $7 (-17.6% implied move). Analyst estimates suggest the stock is overvalued at current levels.
The most bullish Wall Street analyst has a price target of $7 for SGHT, while the most conservative target is $7. The consensus of $7 represents the median expectation. These targets typically reflect 12-month expectations.
SGHT is moderately covered, with 9 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 4 have Buy ratings, 4 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month SGHT stock forecast based on 9 Wall Street analysts shows a consensus price target of $7, with estimates ranging from $7 (bear case) to $7 (bull case). The median consensus rating is "Buy".
Analysts are cautious on SGHT, with 1 Sell ratings and a price target of $7 (-17.6% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
SGHT analyst price targets range from $7 to $7, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $7 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.